Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 614

[455] Futak S. Membrane-permeable arginine-rich peptides and the translocation mecha-
nisms. Adv Drug Delivery Rev 2005;57:547-58.
[456] Kerkis A, Hayashi MA, Yamane T, Kerkis I. Properties of cell penetrating peptides
(CPPs). IUBMB Life 2006;58:7-13.
[457] Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. Novel
Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human
cells for imaging and radiotherapy. Bioconjug Chem 2000;11:762-71.
[458] Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz Jr JD , et al. Normal T-cell , et al. Normal T-cell

response and in vivo magnetic resonance imaging of T cells loaded with HIV trans-
activator-peptide-derived

superparamagnetic nanoparticles. J Immunol Methods

2001;256:89-105.
[459] Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance
and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 2002;13:264-8.
[460] Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-
derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor
cells. Nat Biotechnol 2000;18:410-14.
[461] Josephson L, Tung CH, Moore A, Weissleder R. High efficiency intracellular mag-
netic labeling with novel superparamagnetic-tat peptide conjugate. Bioconjug Chem
1999;10:186-91.
[462] Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-
mediated transduction in the treatment of cancer. Adv Drug Delivery Rev 2005;57:
579-96.
[463] Vocero-Akbani AM, Lissy NA, Dowdy SF. Transduction of full-length tat fusion pro-
teins directly into mammalian cells: analysis of T cell receptor activation-induced cell
death. Methods Enzymol 2000;322:508-21.
[464] Becker-Hapak M, McAllister SS, Dowdy SFM. TAT-mediated protein transduction into
mammalian cells. Methods 2001;24:247-56.
[465] Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, et al.
Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1
induces cell migration. Nat Med 1998;4:1449-52.
[466] Jarver P, Langel U. Cell-penetrating peptides—a brief introduction. Biochim Biophys
Acta 2006;1758:260-3.
[467] Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J.
New advances in the transport of doxorubicin through the blood-brain barrier by a
peptide vector-mediated strategy. Mol Pharmacol 2000;57:679-86.
[468] Snyder EL, Dowdy SF. Cell penetrating peptides in drug delivery. Pharm Res
2004;21:389-93.
[469] Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein.
EMBO J 1991;10:1733-9.
[470] Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: deliv-
ery of a biologically active protein into the mouse. Science 1999;285:1569-72.
[471] Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits ver-
sus prospects. J Pharm Sci 2007;97:144-62.
[472] Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther
1999;6:149-51.
[473] Bechinger B. A dynamic view of peptides and proteins in membranes. Cell Mol Life
Sci 2008;65:3028-39.
[474] Elmquist A, Lindgren M, Bartfai T, Langel U. VE-cadherin-derived cell-penetrating
peptide, pVEC, with carrier functions. Exp Cell Res 2001;269:237-44.